Tufts: Pharma Expected to Spend More on Personalized Medicine

December 2, 2010
Up to half of drug companies’ pipelines involve personalized medicines, and industry expects to increase investment in this area by more than 50 percent over the next five years. Oncology is the lead focus area for personalized medicine, both for drugs on the market and those in development, according to a report from the Tufts Center for the Study of Drug Development. Research and development in oncology relies more on biomarkers and diagnostics than other disease areas, the report says.
Washington Drug Letter